Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind Erasca lost half its value on an IP challenge and a trial death. Now ASCO 2026 looms, Merck is on board, and traders are positioning before the verdict. byVenkateshMay 27, 2026